Aminoquinolines

08/01/2013 - "Drug resistance in malaria parasites is extending in the world particularly in chemical synthesized drugs such as 4- aminoquinolines and aminoalcoholes. "
02/01/2002 - "Cardiotoxicity observed in patients undergoing malaria therapy with aminoquinolines may therefore be due to block of Na(+) channels, with subsequent disturbances of impulse conductance and contractility."
05/01/1998 - "These results confirm that the presence of an OH group in the aryl bridge is not necessary for antimalarial activity and substantiate the view that, despite the appearance of resistant strains, new and existing aminoquinolines still have an important role in treating malaria."
12/01/1958 - "[4-Aminoquinolines in eradication of malaria; epidemiologic evaluation of a single or double dose of 600 milligrams of camoquin]."
01/01/2013 - "Two malaria drug classes, the 8- aminoquinolines and the artemisinins interact with cytochrome P450s and host iron protoporphyrin IX or iron, respectively, to generate toxic metabolites and/or radicals, which kill the parasite by interference with many proteins. "

04/01/1988 - "[Current strategies in the campaign against Plasmodium falciparum malaria in an area resistant to 4-aminoquinolines]."
09/01/1984 - "[Resistance of falciparum malaria to 4-aminoquinolines]."
07/05/1986 - "[Plasmodium falciparum malaria attacks with low or negative parasitemia on returning from areas of endemic resistance to 4-aminoquinolines]."

07/05/1986 - "[Plasmodium falciparum malaria attacks with low or negative parasitemia on returning from areas of endemic resistance to 4-aminoquinolines]."

11/01/2010 - "Therefore, such aminoquinolines might be considered as candidates for the further development of therapeutics to prevent the development of prion diseases."

02/01/1999 - "These data suggest that regulation of the vitamin D-1-hydroxylase in lymphoma cells, the putative source of hormone in lymphoma patients, is refractory to the inhibitory actions of the aminoquinolines and that glucocorticoid-containing antitumor regimens are the antihypercalcemic therapies of choice in lymphoma patients with high 1,25-(OH)2D levels."